"FDA Scrutinizes Semaglutide for Potential Side Effects Amid Weight Loss Drug Debate"

The FDA is investigating reports of serious side effects, including hair loss, suicidal thoughts, and airway obstruction, in patients using GLP-1 diabetes drugs such as Ozempic and Mounjaro. While these drugs are known for their benefits in treating diabetes and aiding weight loss, the reported adverse effects are not currently listed as potential side effects. Novo Nordisk, the manufacturer of several GLP-1 receptor agonists, has acknowledged the FDA's review but maintains that their products are safe and effective when used as directed.